Randomized phase II trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate with ondansetron (ond)/dexamethasone (dex) for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC).

被引：0

作者：

Rolski, J.

Ramlau, R.

Dediu, M.

Russo, M. W.

Ross, G. A.

Mather, R. A.

Bandekar, R. R.

Grunberg, S. M.

机构：

[1] Oncol Ctr, Krakow, Poland

[2] Reg Lung Dis Ctr, Poznan, Poland

[3] Inst Oncol, Bucharest, Romania

[4] GlaxoSmithKline Inc, Collegeville, PA USA

[5] Univ Vermont, Burlington, VT USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8513

引用

下载

页码：471S / 471S

页数：1

共 50 条

[1] Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC)
Herrstedt, J.
Grunberg, S.
Rolski, J.
Bandekar, R. R.
Guckert, M. E.
Camlett, I.
Russo, M. W.
Strausz, J.
Aziz, Z.
Thorn, S.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[2] Phase II trial of the neurokinin-1 antagonist casopitant mesylate for the prevention of chemotherapy-induced nausea/vomiting (CINV) in cancer patients (PTS) receiving highly emetogenic chemotherapy (HEC): Subgroup analysis by cisplatin dose
Rolski, Janusz
Ramlau, Rodryg
Dediu, Mircea
Witman, Philip A.
Bandekar, Rajesh R.
Russo, Mark
ANNALS OF ONCOLOGY, 2006, 17 : 302 - 302
[3] Phase II clinical trial overview of the novel neurokinin-1 (NK-1) antagonist, casopitant, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and highly emetogenic chemotherapy
Rogers, Miriam
Pence, Christine
Russo, Mark
ONCOLOGY NURSING FORUM, 2008, 35 (03) : 557 - 557
[4] Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC).
Arpornwirat, W.
Albert, I.
Hansen, V. L.
Russo, M. A.
Ross, G. A.
Pence, C. D.
Bandekar, R. R.
Grunberg, S. M.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 471S - 471S
[5] Phase 2 Trial Results With the Novel Neurokinin-1 Receptor Antagonist Casopitant in Combination With Ondansetron and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy
Arpornwirat, Wichit
Albert, Istvan
Hansen, Vincent L.
Levin, Jeremey
Bandekar, Rajesh R.
Grunberg, Steven M.
CANCER, 2009, 115 (24) : 5807 - 5816
[6] Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving highly emetogenic chemotherapy (HEC).
Rapoport, Bernardo Leon
Poma, Allen
Hedley, Mary Lynne
Martell, Robert E.
Navari, Rudolph M.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[7] FAVOURABLE PATIENT REPORTED NAUSEA AND QUALITY OF LIFE OBSERVED WITH CASOPITANT, A NOVEL NEUROKININ-1 (NK-1) RECEPTOR ANTAGONIST, IN PATIENTS (PTS) RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC)
Dalal, M.
Guckert, M.
Arondekar, B.
Haiderali, A.
ANNALS OF ONCOLOGY, 2008, 19 : 273 - 274
[8] Safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC)
Urban, Laszlo
Poma, Allen
Dardeno, Michelle Motta
Martell, Robert E.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[9] Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC)
Aziz, Z.
Arpornwirat, W.
Herrstedt, J.
Camlett, I.
Piontek, T.
Ranganathan, S.
Schnyder, J.
Bandekar, R. R.
Levin, J.
Shaharyar, A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[10] ROLAPITANT, A NOVEL NK-1 RECEPTOR ANTAGONIST (NK1-RA), PHASE 3 TRIAL RESULTS IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN SUBJECTS RECEIVING HIGHLY OR MODERATELY EMETOGENIC CHEMOTHERAPY (HEC AND MEC).
Clark-Snow, Rebecca
Nagy, Cindy
Arora, Sujata
Poma, Allen
Navari, Rudolph
ONCOLOGY NURSING FORUM, 2015, 42 (02) : E222 - E223

← 1 2 3 4 5 →